[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial

Advancing cancer therapies. At the speed of light

Advancing cancer therapies. At the speed of light.

Hemerion® develops a unique and disruptive technology to treat glioblastoma.
A breakthrough therapy for glioblastoma patients

A breakthrough therapy for glioblastoma patients

Promising early clinical results

Promising early clinical results

A disruptive technology to tackle brain cancer and glioblastoma

News

Dr Marie-Edith Bonneterre

Hemerion appoints Dr Marie-Edith Bonneterre as Chief Medical Officer

November 17, 2023

Dr Marie-Edith Bonneterre has been appointed Chief Medical Officer (CMO) at Hemerion on September 19, 2023, to steer the medical and clinical strategy of our innovative therapeutic solutions. A specialist… ...

Read more

Deeptech Connect 2023

Hemerion one of 100 start-ups at Deeptech Connect

November 8, 2023

Hemerion is taking part for the first time in Deeptech Connect, an event organized by the SATTs (Tech Transfer Acceleration Companies), which brings together 100 start-ups created from disruptive technologies… ...

Read more

Visit from Guillaume Pépy, President of Initiative France

Hemerion welcomes Guillaume Pépy, Chairman of Initiative France

October 5, 2023

On Tuesday September 26th, Hemerion welcomed Guillaume Pépy, President of Initiative France, at the head of a delegation made up of representatives of the Initiative France network and its partners,… ...

Read more

mail icon

Stay tuned to our clinical advances

Subscribe to our newsletter

They talk about us